

29 September 2014

### **TGA Notice**

The Therapeutic Goods Administration ("TGA") has issued a notice advising that proposed amendments to the Poisons Standard<sup>1</sup> are to be referred to relevant expert advisory committees in November 2014 ("Notice").

Included in the Notice is the intention to schedule Metabolic Pharmaceuticals Pty Ltd's compound AOD9604 in Schedule 4 and Appendix D.

The proposed scheduling will mandate certain controls around the possession and supply of AOD9604 in Australia.

While these controls may more definitely prescribe the legitimate supply of AOD9604, the Board will seek advice on the proposed scheduling, and if necessary, will make a submission as allowed for under the Notice.

Income received by Metabolic Pharmaceuticals from the supply of AOD9604 is not material at present.

<sup>1</sup> The Poisons Standard (the legal title of the Standard for the Uniform Scheduling of Medicines and Poisons) consists of decisions regarding the classification of medicines and poisons into Schedules for inclusion in the relevant legislation of the States and Territories.

**For further information please contact:**

David Williams  
Chairman  
Calzada Limited  
Mobile: + 61 414 383 593  
Email: [dwilliams@kidder.com.au](mailto:dwilliams@kidder.com.au)

David McQuillan  
Acting Joint Managing Director  
Calzada Limited  
Mobile: +1 908 391 2128  
Email: [dmcquillan@calzada.com.au](mailto:dmcquillan@calzada.com.au)

Philip Powell  
Acting Joint Managing Director  
Calzada Limited  
Mobile: + 61 422 312 088  
Email: [ppowell@calzada.com.au](mailto:ppowell@calzada.com.au)

**About Calzada Ltd**

Calzada has 100% ownership of PolyNovo Biomaterials Pty Ltd and Metabolic Pharmaceuticals Pty Ltd. The Company is listed on the Australian Securities Exchange (ASX Code CZD).